These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 20556313

  • 21. Pneumococcal vaccine development.
    Poolman JT.
    Expert Rev Vaccines; 2004 Oct; 3(5):597-604. PubMed ID: 15485339
    [Abstract] [Full Text] [Related]

  • 22. Pneumococcal conjugated vaccine: PHiD-CV.
    Dinleyici EC, Yargic ZA.
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
    [Abstract] [Full Text] [Related]

  • 23. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2005 Sep 16; 54(36):893-7. PubMed ID: 16163262
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.
    Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249
    [Abstract] [Full Text] [Related]

  • 26. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices.
    MMWR Morb Mortal Wkly Rep; 2010 Sep 03; 59(34):1102-6. PubMed ID: 20814406
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C, Lin H, Huang J, Wang H, Cai Q, Fang L, Guo Y.
    Microb Pathog; 2009 Sep 03; 47(3):151-6. PubMed ID: 19467319
    [Abstract] [Full Text] [Related]

  • 29. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
    Ortqvist A, Henckaerts I, Hedlund J, Poolman J.
    Vaccine; 2007 Mar 22; 25(13):2445-50. PubMed ID: 17052816
    [Abstract] [Full Text] [Related]

  • 30. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
    Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, Patterson S, van Alphen AJ, Bonten MJ.
    Neth J Med; 2008 Oct 22; 66(9):378-83. PubMed ID: 18990781
    [Abstract] [Full Text] [Related]

  • 31. Pneumococcal vaccines: an update on current strategies.
    Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R.
    Vaccine; 2004 Jun 02; 22(17-18):2209-20. PubMed ID: 15149779
    [Abstract] [Full Text] [Related]

  • 32. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM.
    Pediatrics; 2008 Mar 02; 121(3):562-9. PubMed ID: 18310206
    [Abstract] [Full Text] [Related]

  • 33. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
    Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC.
    Clin Infect Dis; 2006 Oct 15; 43(8):1004-8. PubMed ID: 16983612
    [Abstract] [Full Text] [Related]

  • 34. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
    Whitney CG.
    Geriatrics; 2003 Oct 15; 58(10):20-2, 25. PubMed ID: 14569639
    [Abstract] [Full Text] [Related]

  • 35. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
    Toltzis P, Jacobs MR.
    Infect Dis Clin North Am; 2005 Sep 15; 19(3):629-45. PubMed ID: 16102653
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.
    Eur J Health Econ; 2008 Feb 15; 9(1):7-15. PubMed ID: 17333089
    [Abstract] [Full Text] [Related]

  • 37. Theory and strategy for Pneumococcal vaccines in the elderly.
    Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N.
    Hum Vaccin Immunother; 2016 Feb 15; 12(2):336-43. PubMed ID: 26406267
    [Abstract] [Full Text] [Related]

  • 38. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.
    Vaccine; 2004 Mar 12; 22(9-10):1138-49. PubMed ID: 15003641
    [Abstract] [Full Text] [Related]

  • 39. [The elderly should be vaccinated against pneumococci].
    Ortqvist A, Hedlund J, Kalin M.
    Lakartidningen; 1999 Mar 17; 96(11):1305-8. PubMed ID: 10194909
    [Abstract] [Full Text] [Related]

  • 40. Call to action on pneumococcal disease: review of vaccination evidence and outcomes of webcast programs.
    Grogg SE, Schultz J.
    J Am Osteopath Assoc; 2015 Jun 17; 115(6 Suppl):S6-25. PubMed ID: 26000904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.